Healthcare Services

Neuro Immunoassay Market Outlook 2026–2035 Driven by Key Growth Factors

April 9, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Neuro Immunoassay Market Over The 2026–2030 Period?

The neuro immunoassay (NIA) market size has demonstrated strong growth in recent years. It is projected to expand from $2.88 billion in 2025 to $3.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The expansion witnessed in prior periods is attributable to a growing demand for sensitive neurological diagnostics, the increasing adoption of immunoassay techniques in neuroscience research, a rising prevalence of neurodegenerative disorders, the expansion of clinical and research laboratories, and an increasing focus on early disease detection and monitoring.

The neuro immunoassay (NIA) market is projected for substantial expansion over the upcoming years, with its valuation expected to reach $4.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This anticipated increase during the forecast period is fueled by factors such as the growing incorporation of neuro immunoassay (NIA) with artificial intelligence (AI) data analysis, heightened investment in biomarker discovery, the increasing uptake of personalized medicine and therapeutic monitoring, the expansion of high-throughput screening platforms, and an uptick in the need for automated and precise immunoassay systems. Key developments expected during this period involve technology-driven breakthroughs improving assay sensitivity and specificity, progress in artificial intelligence (AI)-enabled data interpretation, the evolution of multiplexed and lab-on-a-chip immunoassay systems, intensified research and development efforts in neuro biomarker identification, and innovations in integrated and automated neurodiagnostic platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30676&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Neuro Immunoassay Market?

The projected expansion of the neuro immunoassay market is linked to the rising occurrence of neurological disorders. These disorders are defined as medical conditions impacting the brain, spinal cord, and nerves, which interfere with normal nervous system function, resulting in various impairments such as those affecting movement, cognition, sensation, behavior, or overall bodily control. Their growing prevalence can be attributed to detrimental lifestyle choices, including inadequate diet, lack of physical activity, smoking, high alcohol intake, and persistent stress. Neuro immunoassays facilitate the identification of particular biomarkers within the nervous system, aiding in prompt diagnosis and personalized treatment for individuals with neurological conditions. For example, in April 2024, the National Institutes of Health (NIH), a US-based government agency, reported that approximately 6.9 million Americans aged 65 and older are currently affected by Alzheimer’s dementia, a number expected to almost double to 13.8 million by 2060. Consequently, the escalating incidence of neurological disorders is a key driver for the neuro immunoassay market.

How Is The Neuro Immunoassay Market Segmented Across Key Categories?

The neuro immunoassay market covered in this report is segmented –

1) By Product Type: Reagents And Kits, Analyzers

2) By Technology: Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Rapid Tests, Enzyme-Linked Immunospot Assay (ELISPOT)

3) By Analyte Or Biomarker Type: Amyloid-Beta (Aβ), Tau Protein (p-Tau), Alpha-Synuclein (α-syn), Neurofilament Light Chain (NfL), Autoantibodies, Cytokines, Glial Fibrillary Acidic Protein (GFAP), Neuron-Specific Enolase (NSE), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Brain-Derived Neurotrophic Factor (BDNF)

4) By Application: Alzheimer’s Disease, Parkinson’s Disease (PD), Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA)

5) By End-User: Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Reagents, Western Blotting Kits, Multiplex Assay Kits

2) By Analyzers: Automated Immunoassay Analysers, Point Of Care Immunoassay Analysers, High Throughput Immunoassay Analysers

Which Upcoming Trends Are Expected To Influence The Neuro Immunoassay Market?

Major companies within the neuro immunoassay market are prioritizing the development of advanced solutions, such as blood-based neurological biomarker assays, to enhance disease oversight, improve the precision of prognoses, and support clinical decision-making for neurological disorders. Blood-based neurological biomarker assays are tests designed to quantify specific proteins, including Neurofilament Light Chain (NfL), present in human serum or plasma to evaluate neuronal damage and disease activity. For instance, in June 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, obtained CE marking for its Neurofilament Light Chain blood test, which is intended for use with the Atellica IM Analyzer and ADVIA Centaur systems. This test quantifies NfL levels to assist in predicting the risk of neuronal injury in adults with relapsing multiple sclerosis, complementing clinical, imaging, and laboratory assessments. The CE mark confirms compliance with European In Vitro Diagnostic Regulations, thus expanding access to standardized neuro immunoassay diagnostics across European laboratories.

Which Companies Are Leading Innovation In The Neuro Immunoassay Market?

Major companies operating in the neuro immunoassay market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Meso Scale Diagnostics LLC, Sino Biological Inc., Quanterix Corporation, Cusabio Technology LLC, OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Assay Genie Ltd., Novus Biologicals LLC, Creative Diagnostics, MyBioSource Inc., Immuno-Biological Laboratories Co. Ltd., Boster Biological Technology, Cloud-Clone Corp., FineTest Biotech Inc., Abbexa Ltd.

Read the full neuro immunoassay market report here:

https://www.thebusinessresearchcompany.com/report/neuro-immunoassay-market-report

Which Region Is Expected To Experience The Fastest Growth In The Neuro Immunoassay Market?

North America was the largest region in the neuro immunoassay (NIA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuro immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuro Immunoassay Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30676&type=smp

Browse Through More Reports Similar to the Global Neuro Immunoassay Market 2026, By The Business Research Company

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Immunohematology Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunohematology-global-market-report

immunomodulator global market report

https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795